Annual Drug Patent Expirations for TAFINLAR
Tafinlar is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are six patents protecting this drug.
Drug patent litigation for TAFINLAR.
This drug has one hundred and six patent family members in forty-four countries.
The generic ingredient in TAFINLAR is dabrafenib mesylate. One supplier is listed for this compound. Additional details are available on the dabrafenib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
